Retatrutide is a first-of-its-kind investigational medicine that works on three receptors at once — targeting appetite, metabolism, and liver fat in a single weekly injection. Here's everything Indian patients and doctors need to know.
⚕️ Educational resource only. Retatrutide is investigational — not yet approved or commercially available.
Controls appetite & hunger
Boosts insulin & metabolism
Burns fat & clears liver
Less hunger · Better blood sugar · More fat burning · Cleaner liver
In simple terms — retatrutide is the most powerful weight-loss medicine being tested right now, and it works in a way no other drug has before.
This is the same pathway used by Ozempic and Wegovy. It tells your brain "you're full" and slows down digestion so you eat less naturally.
This second pathway helps your body use insulin better when blood sugar rises. It also makes the nausea from GLP-1 less intense — so the medicine is easier on your stomach.
This is what makes retatrutide special. It tells your liver to burn stored fat and raises your body's calorie-burning rate. No other weight-loss drug does this.
Why does this matter? Ozempic works on 1 receptor. Mounjaro works on 2. Retatrutide works on all 3 — so it reduces what goes in (appetite), improves how your body handles food (metabolism), AND increases what your body burns (energy). That's why trials showed nearly 30% weight loss.
Each generation has gotten more effective. Retatrutide is the latest — and most powerful — step in this journey.
The first GLP-1 drugs. Proved that targeting gut hormones could help people lose weight. Moderate results.
Game-changer. Once-weekly injection producing ~15% average weight loss. Also showed heart benefits. This is what most people know about today.
Added a second receptor (GIP). Result: ~22.5% weight loss. Less nausea than semaglutide. Quickly became the new gold standard.
The first triple agonist. Three receptors working together. Phase 3 trials show 28.7% average weight loss — approaching what bariatric surgery achieves. Still under investigation.
Think of it as attacking obesity from three different angles at the same time — reducing intake, improving processing, and increasing output.
GLP-1 Receptor
GIP Receptor
Glucagon Receptor
Talk to our team about the science behind retatrutide and what it could mean for your situation.
Get It Now →Numbers from actual clinical trials — not marketing claims. Every figure below comes from published, peer-reviewed research.
These are from different trials with different patients — so it's not a perfect apples-to-apples comparison. But the trend is clear.
Data from separate clinical trials. Cross-trial comparisons have limitations. All figures are averages at the highest studied dose.
28.7% is an average, not a promise. Some people lose more, some less. Your result depends on many factors — body type, adherence, diet, activity, and genetics. Clinical trial averages ≠ your personal outcome.
338 people with obesity, 48 weeks. People on 12 mg lost an average of 24.2% body weight. Over 90% lost more than 10%. The weight was still dropping at the end — it hadn't plateaued yet.
Source: New England Journal of Medicine, 2023
People with Type 2 diabetes for an average of 8 years — a tough group. Still lost 17% body weight and dropped HbA1c by up to 2.0% in just 36 weeks. Beat the comparison drug on every measure.
Source: The Lancet, 2023
In people with fatty liver disease, the 12 mg dose cleared 82.4% of liver fat in 24 weeks. 86% of people completely normalised their liver. Placebo group? 0.3% change.
Source: Nature Medicine, 2024
Before any drug can be sold, it needs to pass large-scale Phase 3 trials. Eli Lilly's TRIUMPH program has 5,800+ participants across multiple studies. Here's where things stand.
Who: Adults with obesity, no diabetes
Duration: 80 weeks (longer than Phase 2)
Why it matters: This is THE main trial for weight-loss approval. Results expected mid-2026. Could show 30%+ weight loss.
ClinicalTrials.gov: NCT05929066
Who: People with both obesity and Type 2 diabetes
Duration: 80 weeks
Why it matters: Diabetes makes weight loss harder. This trial tests if triple agonism can overcome that resistance.
ClinicalTrials.gov: NCT05929079
Who: Severe obesity with cardiovascular disease
Result: Up to 22.6% weight loss over 80 weeks. Fewer heart events in the drug group (44 vs 52 in placebo).
Who: 445 people with obesity + knee osteoarthritis
Result: 28.7% average weight loss at 12 mg over 68 weeks — the biggest weight loss ever seen in a Phase 3 drug trial.
Also: 75.8% reduction in knee pain. The weight loss literally took pressure off painful joints.
ClinicalTrials.gov: NCT05869903
Why it matters: Direct comparison between the triple agonist (retatrutide) and the dual agonist (tirzepatide). This will show whether the third receptor actually makes a difference.
Who: ~10,000 patients with heart disease
Goal: Prove retatrutide reduces heart attacks, strokes, and cardiovascular deaths over multiple years. This is the biggest and longest trial.
Result (March 2026): HbA1c dropped by 1.7–2.0% (vs 0.8% placebo). Weight loss of 16.8%. Confirms retatrutide works powerfully for diabetes too.
ClinicalTrials.gov: NCT06297603. Indian sites included AIIMS New Delhi and centres in Gujarat.
Get the latest retatrutide clinical trial news and what it means for Indian patients.
Get It Now →How does retatrutide stack up against the drugs you already know? Here's a side-by-side look based on published data.
| Feature | Retatrutide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptors | GLP-1 + GIP + Glucagon | GLP-1 only | GLP-1 + GIP |
| Type | Triple agonist | Single agonist | Dual agonist |
| Status | Investigational (Phase 3) | Approved globally | Approved globally |
| Trial Weight Loss | 28.7% (TRIUMPH-4) | ~14.9% (STEP-1) | ~22.5% (SURMOUNT-1) |
| Unique Advantage | Burns fat + clears liver fat | Heart outcomes data | Better GI tolerance |
| India | Not available | Available (select brands) | Available (select brands) |
| Injection | Once weekly | Once weekly / oral | Once weekly |
These are results from different trials with different patients. You cannot directly compare numbers between trials. This table is for educational context only and does not establish that one drug is "better" than another for any individual.
The short answer — not yet. Here's exactly where things stand and what's likely to happen next.
As of mid-2026, retatrutide hasn't been approved by CDSCO (India's drug regulator), the US FDA, or any other authority worldwide. It is still in clinical trials. No pharmacy in India can legally sell it.
Eli Lilly has been in talks with Indian regulators. In April 2024, Lilly presented Phase 3 trial protocols to CDSCO's Subject Expert Committee. The committee asked for full domestic safety data once trials finish. So the groundwork is being laid, but approval is still far away.
Indian hospitals are actively participating in global Phase 3 trials. AIIMS New Delhi and centres in Gujarat (Gujarat Endocrine Centre, Avron Hospitals in Ahmedabad) are confirmed trial sites. This means the drug is being tested specifically on Indian patients.
This is based on how drug approvals typically work — not a guarantee from Eli Lilly or CDSCO.
All dates after "Happening Now" are projections. Real timelines depend on trial outcomes, regulatory decisions, and market strategies. Historically, there's a 12–24 month gap between US and India launches for these medicines.
Be the first to know when availability status changes for India.
Get It Now →Like all powerful medicines, retatrutide has side effects. Here's what clinical trials reported — honestly, without sugarcoating.
Nausea, diarrhea, vomiting, and constipation. These hit hardest during the first few weeks when the dose is being increased. Most people find they ease up over time. However, at the 12 mg dose, about 7–13% of trial participants dropped out because of these effects.
Resting heart rate went up by about 7 beats per minute on average. This typically stabilised over time and wasn't linked to dangerous heart rhythms. In fact, the retatrutide group had fewer heart events than placebo.
A small number of people on higher doses reported tingling, "pins and needles," or burning sensations on their skin. This is a new finding specific to retatrutide — doctors are still studying why it happens.
Like all drugs in this class: theoretical thyroid risk (from animal studies), rare pancreatitis risk, and possible kidney stress from dehydration if vomiting/diarrhea is severe. Regular blood tests are essential.
This is trial data — not a green light to self-medicate. Retatrutide is not approved. These side effects were observed under careful medical supervision. Never try to use any unapproved medicine without a doctor's direct oversight.
Trials used a slow step-up approach — starting low and increasing every 4 weeks. This is how the trials worked, not a prescription for you.
This is NOT a dosing guide. The information below describes what was tested in clinical trials. Do not use it to self-administer any unapproved substance. Treatment decisions belong to qualified doctors only.
The slow ramp-up helps minimise stomach side effects. Some patients' best dose might be 9 mg rather than 12 mg, depending on tolerability. Once-weekly subcutaneous injection.
Because retatrutide affects multiple body systems, doctors would need to track several blood markers. Here's what and why.
The drug dramatically lowers blood sugar. If you're also on diabetes medication, there's a risk of going too low. Regular checks prevent dangerous dips.
Retatrutide aggressively clears liver fat. As the fat clears, liver enzymes should normalise. If they don't, it could indicate a different liver problem.
If you're vomiting or having diarrhea, dehydration can stress your kidneys. These tests catch any kidney strain early.
All GLP-1 drugs carry a precautionary thyroid warning based on animal studies. Baseline and periodic screening is standard practice.
Rare risk of pancreatitis with any GLP-1 drug. If lipase levels spike, the medicine needs to be stopped immediately.
Losing 25–30% of body weight means eating significantly less. That can lead to vitamin and mineral deficiencies if not supplemented.
Retatrutide is not a cosmetic weight-loss drug. Clinical trials are focused on people with serious medical conditions.
People with BMI over 35–40 who haven't been able to lose enough weight with diet, exercise, or existing medicines. For them, 28.7% weight loss could be life-changing — and a real alternative to surgery.
Patients with long-standing diabetes who struggle with both blood sugar control and weight. The triple mechanism attacks both problems simultaneously.
Retatrutide's glucagon pathway cleared liver fat more effectively than anything tested before. For people facing liver cirrhosis risk, this could be transformative.
People whose excess weight is destroying their knees (TRIUMPH-4 showed 76% pain reduction), worsening sleep apnoea, or accelerating heart disease.
These are the populations being studied in trials. Whether retatrutide is right for any specific person is a decision only a qualified doctor can make after a proper evaluation.
Since people are desperate for this drug but it's not yet available, fake and dangerous products have flooded the internet. None of them are real pharmaceutical-grade retatrutide.
No pharmacy in India can legally sell retatrutide. If someone is offering it, they're selling you an unverified, unregulated product. Don't risk your health.
Many people are "waiting" for retatrutide while their health gets worse. Doctors strongly advise against this. Here's what you can do right now.
See an endocrinologist or obesity specialist. Get your blood work done. Know your baseline — BMI, HbA1c, liver enzymes, cholesterol. You need this whether or not retatrutide ever comes to India.
Semaglutide and tirzepatide are already approved and available in India. Under doctor supervision, they can produce 15–22% weight loss and dramatically improve heart and diabetes outcomes.
High-protein nutrition, strength training, proper sleep, stress management — these make every medicine work better. Start building the lifestyle base that will amplify any future treatment.
If you start treatment now and retatrutide gets approved later, your doctor can switch you over in a controlled way. You won't lose time — you'll arrive in better shape.
Our team can help you understand your options — both what's available now and what's coming.
Get It Now →Straight answers to the questions Indian patients ask most.
Everything on this page is backed by published clinical data, regulatory filings, and official pharmaceutical communications.
Get educational information about retatrutide research, clinical trials, and the evolving treatment landscape in India.
Get It Now →